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Biol Blood Marrow Transplant 16:560–562, 2010 561Letters to the Editorenvironment, these 2 closely linked objectives are re-
ally served by keeping HSCT in the exclusive domain
of 1 specialty or by opening it up to the legitimate
practitioners of medical immunology. The very begin-
nings of HSCT—by immunologists—may serve as
precedent [4].REFERENCES
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Response to Letter from
Demetrios S. Theodoropoulos,
MD, DSc
We appreciate Dr. Theodoropoulos’ letter and
comments [1]. Dr. Theodoropoulos points out that
the rapid changes in medicine today in both personal-
ized molecular medicine and the emerging field of
regeneration medicine is creating a new landscape
that may alter our projections for the need for an
expanded hematopoietic stem cell transplantation
(HCT) workforce over the next decade. He is correct
that these numbers could ultimately be curbed some-
what from our projections that were made based on
the changing demographics of the aging population
of this country, the expanded indications, and as have
been documented with the recent publication by the
Healthcare Cost and Utilization Project, which dem-
onstrated that bone marrow transplant was associated
with the greatest percentage change and total hospital
stay during the years 2004 to 2007 [2]. However, based
on our current appreciation of personalized molecular
and regeneration medicine, we can at least be assured
that reduction is in transplant procedures will not
occur in the near future.
With regard to his suggestion that the field of HCT
be open to other disciplines, it should be noted that,
currently, FACT and NMDP accreditation recogni-
tion of HCT physicians are for individuals primarily
boarded as internists or pediatricians, with subspecialtytraining in hematology, medical oncology, and/or
immunology [3,4]. However, historically, nearly all
HCT providers have arisen from hematology/oncol-
ogy training programs. Recruiting physicians from
other specialty areas is an intriguing concept
for increasing the HCT workforce, and could be a po-
tential and welcome solution to some of the projected
workforce shortage.
HCT providers must have extensive knowledge of
inpatient medicine in addition to HCT-specific immu-
nology, treatment regimens, infectious complications,
cell collection by apheresis, and bone marrow harvest
and cell processing. HCT patients have a significant
need for inpatient services for management of pancyto-
penia, infectious complications, immunologic complica-
tions like graft-versus host disease (GVHD) and
comorbid diseases exacerbated by the transplant process.
Additionally, it is critical to understand the natural
history of the disorders for which HCT is utilized to
best balance the use of alternative therapies versus
transplantation. Consequently, because about 85% of
transplantsare done to treat malignancies, a firm ground-
ing in the care of oncologic diseases is essential, and the
reason that traditional HCT programs have arisen in
divisions of hematology and/or medical oncology.
One solution for the projected workforce shortage
is an ACGME accredited or nonaccredited fellowship.
Whether a 1-year HCT fellowship would successfully
provide the adequate background in management of
patients with hematologic malignancies or other trans-
plantable malignancies for physicians trained in allergy
and immunology or rheumatology fellowships, both of
which focus on outpatient care, is unclear. It might be
necessary to have a longer period of training for physi-
cians whose initial board certification does not address
competence in all of the oncologic and critical care
areas required for HCT practice. However, there
could be different areas of emphasis during a training
program with the recognition that the management
of the outpatient chronic medical conditions experi-
enced by the posttransplant patient may be better
served by individuals trained in the management of
outpatient immunology and rheumatologic disorders.
Board certification is to demonstrate a newly
trained physician has mastered a knowledge and skill
set to practice a given area of medicine. Recertification
should demonstrate that a physician practicing in the
area is maintaining an adequate knowledge and skill
set to continue to practice in that field. Bone and
marrow transplantation (BMT) fellowships do not
currently have a mandatory curriculum. The closest to
establishing a detailed skill set that should be
mastered by the HCT specialist is the FACT-
required procedural and knowledge skill set. However,
it should be noted that these guidelines do not distinctly
define a skill set needed for the management of complex
multiorgan illnesses in inpatients and outpatients. This
562 Biol Blood Marrow Transplant 16:560–562, 2010Letters to the Editoris an assumed competency from residency, but as stated
in our article [5], the shift in residency education to an
outpatient focus means that such competency should
probably not be presumed, particularly in this era where
hospitalists are evolving and arising as the national stan-
dard for inpatient management. These recognitions
emphasize that a broad multidisciplinary collaborative
effort on future HCT patient management may evolve,
which we would welcome.
Currently, HCT fellowships are not ACGME
accredited because they do not lead to an ABMS board
certification. Although some believe the field should
evolve toward board certification, not all current trans-
plant physicians feel that this step is essential, and there
is concern that it would provide yet another barrier to re-
cruiting physicians to practice in this complex field. Ad-
ditionally, for specialties with small workforces where
the expected numbers of examinees would be fewer
than 50 per year, it is not certain that additional new
board certification would be approved by the national
accrediting body of the American Board of Internal
Medicine or the American Board of Medical Specialties
even if requested. Whether board certification in HCT
would motivate physicians in other disciplines to further
involve themselves in this field when their own field has
a workforce shortage remains unclear.
The ASBMT plans over the next several years to
initiate a series of interventions to address these is-
sues. Plans are underway for ASBMT to publish
a core curriculum for HCT fellowships. To help
HCT practitioners demonstrate continued compe-
tency and to assist with recertification or maintenance
of certification for hematology and medical oncology
boarded practitioners, ASBMT plans to create
a Practice Improvement Module (PIM). ASBMTErratum
In ‘‘Pulmonary, Gonadal, and Central Nervous
System Status after Bone Marrow Transplantation
for Sickle Cell Disease’’ (Walters et al., Biol Blood
Marrow Transplant 2009:16:263–272) the following
author was omitted: Ann Haight, MD, Emory
University, Atlanta, GA.recognizes that the field needs to improve training
and credentialing. These incremental steps will be
a good start. Looking toward more aggressive
recruitment of expertise from other medical disci-
plines may be a new initiative worthy of early, versus
later, exploration.REFERENCES
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